RANCHO CORDOVA, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, announced today that it will be presenting and meeting with investors at the 8th annual LD Micro Main Event on Wednesday, December 2 in Bel Air, California at the Luxe Sunset Hotel. 

• Presenter: Robin C. Stracey, CEO & Director
• Date and Time: Wednesday, December 2 at 8:00am PT/11:00am ET
• Venue: Luxe Sunset Hotel
• Topic Corporate Presentation

To set up a one-on-one meeting with Robin Stracey, CEO & Director of Cesca Therapeutics, please contact Kirin Smith, Chief Operations Officer of PCG Advisory Group at, + 1-646-863-6519.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational in June. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:

• SurgWerks™; proprietary stem cell therapy point-of-care kits for the treatment of vascular and orthopedic indications that integrate the following indication specific elements:
  • Cell harvesting
  • Cell processing and selection
  • Cell diagnostics
  • Cell delivery
• CellWerks^TM; an integrated system which includes a protocol, disposables and equipment for intra-laboratory use in treatment of oncological and hematological disorders.
• The AutoXpress^® (AXP); a proprietary automated device, along with companion sterile blood processing disposables, for the harvesting of stem cells from cord blood.
• The MarrowXpress^™ (MXP); a device and disposable system based on the AutoXpress platform for the isolation and concentration of stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control and optical sensors and concentrates white blood cells from bone marrow to a user- defined volume in 40 minutes while retaining over 90% of mononuclear cells (MNCs).
• The BioArchive^® System; an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries, for cryopreservation and archiving of cord blood stem cell units for transplant.

CONTACT: Cesca Therapeutics Inc.
         http://www.cescatherapeutics.com
         
         Investor Contact: Kirin Smith, PCG Advisory Group
         646-863-6519, or ir@cescatherapeutics.com
         
         Media Contact: Sean Leous, PCG Advisory Group
         646-863-8998 or sleous@pcgadvisory.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.